FREE US SHIPPING OVER $200 · A2LA-ACCREDITED HPLC VERIFIED

Stillwater BioLabs
Wound-Assay & Matrix Research

BPC-157 + TB-500 Blend

What's in the vial:5mgBPC-157+5mgTB-500
$80

A lyophilized blend combining BPC-157 (15 aa, 1419.53 g/mol) and TB-500 (43 aa, 4963.50 g/mol) for in-vitro co-incubation and synergy assays.

$80

1 vial × $80 each

Add 3+ to unlock
volume pricing

Size:
VisaMastercardAmerican Express

Pay with Visa, Mastercard, or AMEX · ACH bank transfer saves 5%

Free US shipping on orders over $200, with tracking provided.

Third-party tested

For laboratory research use only. Not for human or veterinary use. Not for diagnostic or therapeutic use.

Supplied to qualified labs and institutional buyers. Institutional use & buyer eligibility

Characteristics

Characteristics of BPC-157 + TB-500 Blend
PropertyValue
ComponentsBPC-157 (pentadecapeptide) + TB-500 (Thymosin Beta-4 fragment)
BPC-157 Molecular FormulaC₆₂H₉₈N₁₆O₂₂
TB-500 Molecular FormulaC₂₁₂H₃₅₀N₅₆O₇₈S
BPC-157 Molar Mass1419.53 g/mol
TB-500 Molar Mass4963.44 g/mol
Physical FormLyophilized powder blend
SolubilityBoth components freely soluble in water and aqueous laboratory solvent
Organoleptic ProfileWhite to off-white lyophilized powder; odorless
Storage ConditionsStore lyophilized at -20°C; reconstituted solution stable at 2-8°C for up to 10 days
CompositionLyophilized blend of BPC-157 acetate and Thymosin Beta-4 acetate

How is BPC-157 + TB-500 Blend Used in Research?

The BPC-157 + TB-500 blend is a lyophilized research formulation combining two synthetic peptides for in-vitro co-incubation and synergy assays. BPC-157 is a 15-amino acid synthetic peptide (1419.53 g/mol) and TB-500 is a 43-amino acid synthetic peptide (4963.50 g/mol). The blend is supplied as a laboratory research standard for characterizing the two-component system across a panel of in-vitro assays. Not for use in any living organism.

Characterization workflows profile the blend in endothelial tube-formation assays (where BPC-157 is used as a reference compound), cell-migration model assays (where TB-500 is used as a reference compound), and combined receptor-binding studies. Standard laboratory readouts include tube-formation quantification on Matrigel, scratch-assay cell-migration kinetics, and VEGF-pathway marker analysis in cultured endothelial cell lines.

Researchers use this blend as a two-component reference mixture for analytical method development (HPLC/LC-MS comparability work) and for co-activation assays investigating whether the two synthetic peptides produce additive or non-additive signals across the above in-vitro endpoints.

This product is supplied in a lyophilized form and requires reconstitution prior to laboratory handling. For research and laboratory use only. Not for human or veterinary consumption.

Areas of Study

In-Vitro Co-Incubation Assays

Applied as a two-component reference mixture in endothelial tube-formation assays, cell-migration scratch assays, and VEGF-pathway marker panels.

Synergy Characterization

Profiled for additive versus non-additive in-vitro signals across combined receptor-binding and cell-culture readouts.

Analytical Method Development

Used in HPLC/LC-MS comparability work requiring simultaneous identification of the 15- and 43-amino acid components.

Structural Reference

Serves as a combined identity and purity reference for the two synthetic peptides in laboratory characterization workflows.

Receptor-Binding Studies

Applied in parallel binding panels to characterize each component's receptor signature within the two-component system.

References

  1. [1]Sikiric P, Seiwerth S, Rucman R, et al. (2018). Stable gastric pentadecapeptide BPC 157 in preclinical research. Current Pharmaceutical Design, 24(18), 1990-2001.
  2. [2]Goldstein AL, Hannappel E, Sosne G, Kleinman HK. (2012). Thymosin β4: a multi-functional regenerative peptide. Expert Opinion on Biological Therapy, 12(1), 37-51.
  3. [3]Sosne G, Qiu P, Goldstein AL, Wheater M. (2010). Biological activities of thymosin β4 defined by active sites in short peptide sequences. FASEB Journal, 24(7), 2144-2151.
  4. [4]Cerovecki T, Bojanic I, Brcic L, et al. (2010). Pentadecapeptide BPC 157 (PL 14736) in ligament preclinical models. Journal of Orthopaedic Research, 28(9), 1155-1161.
  5. [5]Philp D, Huff T, Gho YS, et al. (2003). The actin binding site on thymosin β4 promotes angiogenesis. FASEB Journal, 17(14), 2103-2105.

Disclaimer: The information provided is for research reference only and does not constitute medical advice. Products are sold strictly for in-vitro research use.

Certificate of Analysis (COA)

Third-Party Verified Quality

Every batch of BPC-157 + TB-500 Blendis independently tested by an A2LA-accredited (ISO 17025:2017) third-party laboratory using HPLC-UV/VIS for purity and measured quantity. Each COA carries the lab's signed report and a batch-specific lot number. We publish these results publicly so you can verify exactly what you're getting.

View Lab Results

Related Products

GIP3 — ≥98% purity, Lyophilized Powder
Metabolic Pathway Research

GIP3

10mg – 30mg

Triple-agonist research peptide targeting GIP, GLP-1, and glucagon receptors in preclinical metabolic studies.

From $100
View Details
BPC-157 — ≥99% purity, Lyophilized PowderBest Seller
Wound-Assay & Matrix Research

BPC-157

5mg – 10mg

A 15-amino acid synthetic peptide fragment derived from human gastric juice protein, supplied as a lyophilized research reference standard for in-vitro cytoprotection assays and receptor-binding studies.

From $45
View Details
TB-500 — ≥99% purity, Lyophilized Powder
Wound-Assay & Matrix Research

TB-500

5mg – 10mg

A 43-amino acid synthetic peptide (Thymosin Beta-4 fragment) supplied as a lyophilized powder for in-vitro actin-binding assays and cell-migration studies.

From $60
View Details